[Music] Hi. Hello. From what uh hearing from what you guys think about me, I sound like a very fun um energetic uh person to be around. Um, I am sorry in advance if this talk is not going to be as fun as you imagine it's going to be. Uh, because I don't think you all understand how much this moment matters to me because for the past few years I sort of disappeared. Not that the world was waiting. Not that any of you may have realized or not realized. But I did disappear. My family knows. A lot of my family ...

Group 1 - Tonix Pharmaceuticals is a clinical-stage biotechnology firm focused on developing TNX-102 SL, a compound aimed at improving sleep quality in fibromyalgia patients [1] - The FDA is currently reviewing TNX-102 SL, with a Prescription Drug User Fee Act (PDUFA) date set for August 15, 2025 [1] - The company aims to bridge the gap between scientific advancements and financial strategies in the healthcare sector, assisting clients in uncovering hidden value and assessing risks [1]

A copy of the Company's poster presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the EULAR website here. CHATHAM, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced a poster presentation at ...